AU6920898A - Antisense inhibition of human stat-6 - Google Patents

Antisense inhibition of human stat-6

Info

Publication number
AU6920898A
AU6920898A AU69208/98A AU6920898A AU6920898A AU 6920898 A AU6920898 A AU 6920898A AU 69208/98 A AU69208/98 A AU 69208/98A AU 6920898 A AU6920898 A AU 6920898A AU 6920898 A AU6920898 A AU 6920898A
Authority
AU
Australia
Prior art keywords
antisense inhibition
human stat
stat
human
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU69208/98A
Inventor
Brent Graham
Helena Catharina Herlaar
Sandra Jane Hill
Judith Ann Dr. Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU6920898A publication Critical patent/AU6920898A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU69208/98A 1997-03-13 1998-03-11 Antisense inhibition of human stat-6 Abandoned AU6920898A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9705212 1997-03-13
GBGB9705212.0A GB9705212D0 (en) 1997-03-13 1997-03-13 Chemical compounds
PCT/EP1998/001400 WO1998040478A2 (en) 1997-03-13 1998-03-11 Antisense inhibition of human stat-6

Publications (1)

Publication Number Publication Date
AU6920898A true AU6920898A (en) 1998-09-29

Family

ID=10809179

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69208/98A Abandoned AU6920898A (en) 1997-03-13 1998-03-11 Antisense inhibition of human stat-6

Country Status (3)

Country Link
AU (1) AU6920898A (en)
GB (1) GB9705212D0 (en)
WO (1) WO1998040478A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115634A1 (en) 2002-12-11 2004-06-17 Isis Pharmaceuticals, Inc. Modulation of stat 6 expression
GB0404209D0 (en) 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
DE102004026309A1 (en) * 2004-05-26 2005-12-29 Haarlems Allergenen Laboratorium B.V. Pharamceutical composition for the treatment of allergic diseases, pathological pathway changes and cancer by modulation of Stat6 gene expression
US20060258610A1 (en) * 2005-05-12 2006-11-16 Isis Pharmaceuticals, Inc. Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002023A1 (en) * 1995-06-30 1997-01-23 Smithkline Beecham Corporation USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS

Also Published As

Publication number Publication date
GB9705212D0 (en) 1997-04-30
WO1998040478A2 (en) 1998-09-17
WO1998040478A3 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
AU6647700A (en) Antisense modulation of human rho family gene expression
PL337442A1 (en) Expression adjustment of quinolane phosphoribozyltransferase
AU5587499A (en) Antisense modulation of g-alpha-16 expression
AU5239399A (en) Antisense modulation of g-alpha-13 expression
EP1009860A4 (en) Antisense oligonucleotide inhibition of ras
AU3640997A (en) Iontophoretic delivery of integrin inhibitors
AU4325199A (en) Antisense modulation of g-alpha-11 expression
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
GB9514437D0 (en) Inhibition of gene expression
ZA988641B (en) Reduction of hair growth
GB9514435D0 (en) Inhibition of gene expression
EP0950060A4 (en) Antisense inhibition of human adhesion molecules
AU2585197A (en) Antisense approach to gene inhibition
AU6920898A (en) Antisense inhibition of human stat-6
GB2326116B (en) Treatment of chocolate
AU8874198A (en) Antisense treatment of pulmonary hypertension
AU6578298A (en) Antisense inhibition of angiogenin expression
PL335675A1 (en) Anticonvulsive derivatives of isoquinolinbenzamide
AU5110299A (en) Antisense modulation of rhog expression
IL124387A0 (en) Preparation of 5-Methyleneoxazolines
AU9082698A (en) Treatment of inflammatory conditions
AU7545998A (en) Treatment of osteoporosis
GB9720087D0 (en) Preparation of cyclopropylethyne and intermediates for preparation of cyclopropylethyne
GB9706060D0 (en) Inhibition of gene expression
GB9703663D0 (en) Inhibition of gene expression